Colorectal cancer (CRC) is a significant global health issue, with diet and lifestyle being critical factors in its development and prevention. Among dietary components, polyunsaturated fatty acids (PUFAs) have been extensively studied for their role in CRC.
Colorectal cancer (CRC) is a significant global health issue, with diet and lifestyle being critical factors in its development and prevention. Among dietary components, polyunsaturated fatty acids (PUFAs) have been extensively studied for their role in CRC. PUFAs are classified into two main types: omega-3 and omega-6 fatty acids, which have contrasting effects on colorectal carcinogenesis.
**Omega-3 PUFAs**, found in fish oils (e.g., salmon, mackerel) and plant-based sources (e.g., flaxseeds, walnuts), include eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA). These fatty acids exhibit anti-inflammatory, anti-proliferative, and pro-apoptotic properties. They reduce inflammation by inhibiting pro-inflammatory mediators like prostaglandin E2 (PGE2), downregulate cyclooxygenase-2 (COX-2), and promote apoptosis in colorectal epithelial cells. Epidemiological studies suggest that higher omega-3 PUFA intake is associated with a reduced CRC risk, particularly in populations with diets rich in fish.
In contrast, **omega-6 PUFAs**, found in vegetable oils (e.g., soybean, sunflower) and nuts, include linoleic acid (LA) and arachidonic acid (AA). These fatty acids can promote inflammation and tumor progression by serving as precursors for pro-inflammatory mediators such as PGE2, which enhances cell proliferation, angiogenesis, and immune evasion. High omega-6 PUFA intake, especially when coupled with a high omega-6:omega-3 ratio, has been linked to an increased CRC risk.
Balancing dietary omega-3 and omega-6 PUFAs is crucial for CRC prevention. A low omega-6 to omega-3 ratio (<4:1) is recommended. Additionally, omega-3 PUFAs, particularly EPA and DHA, are being explored as chemopreventive agents, with promising results in reducing rectal polyp burden in familial adenomatous polyposis (FAP) patients.
This review redefines dopamine (DA) signaling beyond its classical role in reward processing, positioning dopaminergic circuits as central regulators of feeding behavior, metabolic sensing, and energy homeostasis. The authors describe how distributed dopamine ensembles across...
Introduction Atherosclerosis has traditionally been viewed as a lipid-driven disease. However, emerging evidence highlights a critical role of chronic inflammation and immune activation, with the gut microbiota now recognised as a key modulator of vascular...
Clinical Summary In this randomized international trial (COBRRA), investigators compared the bleeding risk of apixaban vs. rivaroxaban in patients with acute venous thromboembolism (VTE), including pulmonary embolism and proximal deep-vein thrombosis. A total of 2,760...
The American College of Gastroenterology (ACG) 2025 meeting is a prominent annual event where groundbreaking research, clinical studies, and advancements in gastroenterology are presented. At the ACG 2025 meeting, several impactful studies were showcased, providing...
Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ArLD) often coexist, presenting a complex clinical challenge that requires careful consideration of pharmacological treatment. Below is a detailed explanation starting from definitions, the need for pharmacological...
Copper dysregulation plays a central role in the pathogenesis of Wilson disease (WD). The disease arises from the body’s inability to regulate copper levels, leading to its accumulation and subsequent toxicity. Below is a detailed...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.